Repurposing an Antiviral Drug against SARS-CoV-2 Main Protease

Angew Chem Int Ed Engl. 2021 Oct 25;60(44):23492-23494. doi: 10.1002/anie.202107481. Epub 2021 Sep 21.

Abstract

This article highlights recent pioneering work by Günther et al. towards the discovery of potential repurposed antiviral compounds (peptidomimetic and non-peptidic) against the SARS-CoV-2 main protease (Mpro ). The antiviral activity of the most potent drugs is discussed along with their binding mode to Mpro as observed through X-ray crystallographic screening.

Keywords: SARS-CoV-2; X-ray crystallographic screening; allosteric inhibitors; antiviral drugs; drug screening.

Publication types

  • Review

MeSH terms

  • Allosteric Site
  • Animals
  • Antiviral Agents / chemistry
  • Antiviral Agents / pharmacology*
  • Chlorocebus aethiops
  • Coronavirus 3C Proteases / antagonists & inhibitors*
  • Crystallography, X-Ray
  • Drug Repositioning*
  • Molecular Structure
  • Protease Inhibitors / chemistry
  • Protease Inhibitors / pharmacology*
  • SARS-CoV-2 / enzymology*
  • Vero Cells

Substances

  • Antiviral Agents
  • Protease Inhibitors
  • 3C-like proteinase, SARS-CoV-2
  • Coronavirus 3C Proteases